High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias

Leukemia

Volumn 24, Issue 11, 2010, Pages 1859-1866

  Morisot, S ^a   Wayne, A S ^b   Bohana Kashtan, O ^a   Kaplan, I M ^a   Gocke, C D ^c   Hildreth, R ^a   Stetler Stevenson, M ^b   Walker, R L ^b   Davis, S ^b   Meltzer, P S ^b   Wheelan, S J ^d   Brown, P ^d   Jones, R J ^d   Shultz, L D ^e   Civin, C I ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e JACKSON LABORATORY   (United States)

Author keywords

childhood acute lymphoblastic leukemia; leukemia stem cells; xenograft

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CELL PROLIFERATION; CELL TRANSPLANTATION; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; KARYOTYPE; LEUKEMIA CELL; MOUSE; NONHUMAN; PRECURSOR B ACUTE LYMPHOBLASTIC LEUKEMIA; PRIORITY JOURNAL; RISK FACTOR; SPLEEN CELL; STEM CELL;

EID: 78149464805     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.184     Document Type: Article

References (57)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.
2. Centers for Disease Control and Prevention (CDC). Trends in childhood cancer mortality-United States 1990-2004. MMWR Morb Mortal Wkly Rep 2007; 56: 1257-1261.
3. Larson S, Stock W. Progress in the treatment of adults with acute lymphoblastic leukemia. Curr Opin Hematol 2008; 15: 400-407.
4. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458: 719-724.
5. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003; 300: 949.
6. Levis M, Murphy KM, Pham R, Kim KT, Stine A, Li L et al. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood 2005; 106: 673-680.
7. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339-9344.
8. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
9. Park CY, Tseng D, Weissman IL. Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol Ther 2009; 17: 219-230.
10. Bachmann PS, Lock RB. In vivo models of childhood leukemia for preclinical drug testing. Curr Drug Targets 2007; 8: 773-783.
11. Liem NL, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, Choi S et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004; 103: 3905-3914.
12. Lock RB, Liem N, Farnsworth ML, Milross CG, Xue C, Tajbakhsh M et al. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 2002; 99: 4100-4108.
13. Baersch G, Mollers T, Hotte A, Dockhorn-Dworniczak B, Rube C, Ritter J et al. Good engraftment of B-cell precursor ALL in NOD-SCID mice. Klin Padiatr 1997; 209: 178-185.
14. Lumkul R, Gorin NC, Malehorn MT, Hoehn GT, Zheng R, Baldwin B et al. Human AML cells in NOD/SCID mice: engraftment potential and gene expression. Leukemia 2002; 16: 1818-1826.
15. Monaco G, Konopleva M, Munsell M, Leysath C, Wang RY, Jackson CE et al. Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival. Stem Cells 2004; 22: 188-201.
16. Gaidzik V, Dohner K. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 2008; 35: 346-355.
17. Ailles LE, Gerhard B, Kawagoe H, Hogge DE. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 1999; 94: 1761-1772.
18. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006; 6: 559-565.
19. Crazzolara R, Cisterne A, Thien M, Hewson J, Baraz R, Bradstock KF et al. Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood 2009; 113: 3297-3306.
20. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 2005; 106: 1565-1573.
21. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in trans-lational biomedical research. Nat Rev Immunol 2007; 7: 118-130.
22. McDermott SP, Eppert K, Lechman E, Doedens M, Dick JE. Comparison of human cord blood engraftment between immuno-compromised mouse strains. Blood 2010; 116: 193-200.
23. Prochazka M, Gaskins HR, Shultz LD, Leiter EH. The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency. Proc Natl Acad Sci USA 1992; 89: 3290-3294.
24. Castor A, Nilsson L, Astrand-Grundstrom I, Buitenhuis M, Ramirez C, Anderson K et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 2005; 11: 630-637.
25. Gluck U, Zipori D, Wetzler M, Berrebi A, Shaklai M, Drezen O et al. Long-term proliferation of human leukemia cells induced by mouse stroma. Exp Hematol 1989; 17: 398-404.
26. Ito C, Kumagai M, Manabe A, Coustan-Smith E, Raimondi SC, Behm FG et al. Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis. Blood 1999; 93: 315-320.
27. Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, Flores T, Garcia-Sanz R, Gonzalez M et al. A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia. Blood 2000; 95: 1007-1013.
28. Cox CV, Evely RS, Oakhill A, Pamphilon DH, Goulden NJ, Blair A. Characterization of acute lymphoblastic leukemia progenitor cells. Blood 2004; 104: 2919-2925.
29. Campana D, Iwamoto S, Bendall L, Bradstock K. Growth requirements and immunophenotype of acute lymphoblastic leukemia progenitors. Blood 2005; 105: 4150.
30. Kamel-Reid S, Letarte M, Doedens M, Greaves A, Murdoch B, Grunberger T et al. Bone marrow from children in relapse with pre-B acute lymphoblastic leukemia proliferates and disseminates rapidly in scid mice. Blood 1991; 78: 2973-2981.
31. Barabe F, Kennedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. Science 2007; 316: 600-604.
32. le Viseur C, Hotfilder M, Bomken S, Wilson K, Rottgers S, Schrauder A et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 2008; 14: 47-58.
33. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
34. Kong Y, Yoshida S, Saito Y, Doi T, Nagatoshi Y, Fukata M et al. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 2008; 22: 1207-1213.
35. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25: 1315-1321.
36. Agliano A, Martin-Padura I, Mancuso P, Marighetti P, Rabascio C, Pruneri G et al. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer 2008; 123: 2222-2227.
37. Dick JE. Looking ahead in cancer stem cell research. Nat Biotechnol 2009; 27: 44-46.
38. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593-598.
39. Spiegel A, Kollet O, Peled A, Abel L, Nagler A, Bielorai B et al. Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling. Blood 2004; 103: 2900-2907.
40. Mazurier F, Doedens M, Gan OI, Dick JE. Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells. Nat Med 2003; 9: 959-963.
41. Rehe K, Wilson K, McNeill H, Schrappe M, Irving J, Vormoor HJ. Disease propagating blasts in standard and high risk acute lymphoblastic leukemia are frequent and of diverse immuno-phenotype. Blood 2009; 114: 22 (abstract no. 1421).
42. Schmitz M, Mirkowska P, Breithaupt P, Meissner B, Cario G, Schrauder A et al. Leukemia-initiating cells are frequent in very high risk childhood acute lymphoblastic leukemia and give rise to relatively stable phenotypes in immunodeficient mice. Blood 2009; 114: 22 (abstract no. 86).
43. Cheung AM, Fung TK, Fan AK, Wan TS, Chow HC, Leung JC et al. Successful engraftment by leukemia initiating cells in adult acute lymphoblastic leukemia after direct intrahepatic injection into unconditioned newborn NOD/SCID mice. Exp Hematol 2009; 38: 3-10.
44. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y et al. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103: 2332-2336.
45. Uckun FM, Sather HN, Waurzyniak BJ, Sensel MG, Chelstrom L, Ek O et al. Prognostic significance of B-lineage leukemic cell growth in SCID mice: a Children's Cancer Group Study. Leuk Lymphoma 1998; 30: 503-514.
46. Van Hennik PB, de Koning AE, Ploemacher RE. Seeding efficiency of primitive human hematopoietic cells in nonobese diabetic/severe combined immune deficiency mice: implications for stem cell frequency assessment. Blood 1999; 94: 3055-3061.
47. Vormoor HJ. Malignant stem cells in childhood acute lymphoblastic leukemia: the stem cell concept revisited. Cell Cycle 2009; 8: 996-999.
48. Hotfilder M, Rottgers S, Rosemann A, Jurgens H, Harbott J, Vormoor J. Immature CD34+CD19- progenitor/stem cells in TEL/AML1-positive acute lymphoblastic leukemia are genetically and functionally normal. Blood 2002; 100: 640-646.
49. Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, Soneji S et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008; 319: 336-339.
50. Hotfilder M, Rottgers S, Rosemann A, Schrauder A, Schrappe M, Pieters R et al. Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells. Cancer Res 2005; 65: 1442-1449.
51. Cox CV, Diamanti P, Evely RS, Kearns PR, Blair A. Expression of CD133 on leukemia initiating cells in childhood ALL. Blood2009; 113: 3287-3296.
52. Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008; 112: 568-575.
53. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007; 317: 337.
54. Kennedy JA, Barabe F, Poeppl AG, WangJC, DickJE. Comment on 'Tumor growth need not be driven by rare cancer stem cells'. Science 2007; 318: 1722.
55. Adams JM, Kelly PN, Dakic A, Nutt SL, Strasser A. Response to Comment on 'Tumor growth need not be driven by rare cancer stem cells'. Science 2007; 318: 1722d.
56. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006; 442: 818-822.
57. Adams JM, Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res 2008; 68: 4018-4021.